SPE2D2-25-D-0003 - Methylphenidate HCL ER Tablets Contract
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-25-D-0003
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents4
The Defense Logistics Agency (DLA) Troop Support has issued an award notice for contract SPE2D2-25-D-0003, pertaining to the supply of Methylphenidate Hydrochloride Extended Release (ER) Tablets. This contract falls under the North American Industry Classification System (NAICS) code 325412, which covers Pharmaceutical Preparation Manufacturing, and is further classified under Product Service Code 6505, indicating a focus on drugs and biologicals.
The current notice announces the issuance of modification P0004, which exercises the first-year option of the contract. This action ensures the continued procurement and supply of Methylphenidate HCL ER Tablets, a critical pharmaceutical product used in the treatment of attention deficit hyperactivity disorder (ADHD) and related conditions. The scope of the contract encompasses the manufacturing and delivery of these extended-release tablets to meet the ongoing requirements of federal agencies supported by DLA Troop Support.
Key objectives of this procurement include maintaining a reliable supply chain for essential medications, ensuring product quality and regulatory compliance, and supporting the operational readiness of federal entities. Contractors engaged in this contract are expected to adhere to stringent manufacturing standards, deliver products in accordance with specified timelines, and comply with all applicable federal regulations governing pharmaceutical preparations.
The contracting activity is managed by DLA Troop Support, a federal office responsible for sourcing and supplying medical and pharmaceutical products to military and other government customers. The primary point of contact for this contract is Courtney Hunter, who can be reached at [email protected] or by phone at 445-737-3585. A secondary contact, Jason C. Wray, is also available at [email protected] or (445) 737-6304 for additional inquiries.
This award notice is currently active and was posted on November 20, 2025. Interested parties can access further details and related attachments through the official SAM.gov opportunity listing at https://sam.gov/opp/6122d2ce1e814050af4585a88080e05b/view.
Contractors considering this opportunity should note that the contract is structured to support long-term supply needs, with option years available to extend performance. The requirements for pharmaceutical manufacturing expertise, regulatory compliance, and consistent product delivery will remain constant throughout the contract lifecycle. No specific set-aside requirements or special considerations are indicated in the notice.
Overall, this contract represents a significant opportunity for qualified pharmaceutical manufacturers to partner with DLA Troop Support in delivering high-quality, extended-release Methylphenidate HCL tablets to federal customers, ensuring continuity of care and operational support.